North East and North Cumbria
ICS Formulary
 
back
4 Central nervous system
04-09-01 Dopamine receptor agonists

Apomorphine
Formulary
  • 5mg/1ml (20ml) solution for infusion for infusion pumps & 10mg/1ml (3ml) solution for injection cartridges (Dacepton®) - NEW PATIENTS
  • 30mg/3ml solution for injection (APO-go®) - Patients commenced on treatment prior to July 2022 can continue on APO-go® (including 50mg/10ml solution for infusion pre-filled syringes for infusion pumps)
  • Apomorphine 10mg lozenges are also approved (RVI) unlicensedUnlicensed
Link  MHRA Drug Safety Update (April 2016): Apomorphine with domperidone: minimising risk of cardiac side effects
Link  NENC Shared Care Protocol - Apomorphine injection for patients within adult services with Parkinson’s disease

Amber View adult BNF  View SPC online  View childrens BNF
Bromocriptine
Formulary

Green plus View adult BNF  View SPC online  View childrens BNF
Pramipexole
Formulary
  • Approved for second line use in Parkinson's disease. 

Green plus View adult BNF  View SPC online  View childrens BNF
Ropinirole
Formulary
  • Ropinirole once daily formulation is only approved for use in Parkinson’s disease patients with proven compliance. Green plus
  • Approved for first line use in patients with restless legs syndrome. Green

 

View adult BNF  View SPC online  View childrens BNF
Rotigotine
Formulary
  • For use on the advice of specialists in the treatment of Parkinson's disease. Mainly for use in patients who have difficulty with swallowing.
  • Approved for second line use in patients with restless legs syndrome.

Green plus View adult BNF  View SPC online  View childrens BNF